In this chapter, we will provide a brief review of the attributes of the Shiga toxin (Stx) family with emphasis on the importance of these toxins in the pathogenesis of disease caused by E. coli O157: H7 and other Shiga toxin-producing E. coli (STEC). We will also describe a modification of our streptomycin (str)-treated, orally-infected mouse model (23, 24) that permits the assessment of the relative virulence of various E. coli O157:H7 strains. In addition, we will illustrate how the type (s) of Stx produced by an E. coli strain is linked to virulence of that isolate when fed to str-treated mice. Lastly, we will underscore the role that activation of Stx2d by intestinal mucus plays in enhancing the pathogenicity of an infecting STEC strain that produces Stx2d.
OVERVIEW
In this chapter, we will provide a brief review of the attributes of the Shiga toxin (Stx) family with emphasis on the importance of these toxins in the pathogenesis of disease caused by E. coli O157: H7 and other Shiga toxin-producing E. coli (STEC). We will also describe a modification of our streptomycin (str)-treated, orally-infected mouse model (23, 24) that permits the assessment of the relative virulence of various E. coli O157:H7 strains. In addition, we will illustrate how the type (s) of Stx produced by an E. coli strain is linked to virulence of that isolate when fed to str-treated mice. Lastly, we will underscore the role that activation of Stx2d by intestinal mucus plays in enhancing the pathogenicity of an infecting STEC strain that produces Stx2d.
BACKGROUND Characteristics of Stxs
Shiga toxin produced by Shigella dysenteriae type 1, which is considered the prototype for the Stx family, was first described in 1903 by Conradi (2) and, independently, by Neisser and Shiga (14) . Over the ensuing 95 years, Shiga toxin has been purified to homogeneity, characterized biologically and biochemically, and the genes encoding the toxin cloned and sequenced [reviewed in (17) ]. In aggregate, these studies taken with X-ray crystallographic analysis (3) have culminated in a picture of Shiga toxin as a bi-partite molecule that is comprised of a single A polypeptide S108 Shiga toxin-producing Escherichia coli (STEC) That certain diarrheagenic E. coli strains make a toxin related to Shiga toxin was first described by our laboratory in an abstract in 1978 (18) and subsequently confirmed in apeer-reviewed publication in 1982 (15). On a parallel tract, Konowalchuk and colleagues reported in 1978 that some E. coli isolates make a toxin that kills Vero cells (8). We subsequently showed that these Vero cell toxins and the Shiga toxins of E. coil were different names for the same proteins (16). Indeed, production of Stxs was ultimately demonstrated to be a hallmark trait of enterohemorrhagic E. coil (EHEC) O157: H7, the most common infectious cause of bloody diarrhea in the United States and the most frequent preceding event for the development of the hemolytic uremic syndrome (HUS) [see ref. (4) for a comprehensive review of E. coil O157:H7]. EHEC [so named by Levine (9)] are a subset of STEC that in addition to maintenance of a large plasmid and synthesis of Stxs also express the adhesin intimin. Intimin is encoded in the locus of enterocyte effacement (LEE), a newly described pathogenicity island that is also found in enteropathogenic E. coil (12). The epidemiological link between Stx production by an E. coil S109 isolate and the development of HUS after infection by that strain was established by Karmali and colleagues in their seminal papers (6, 7).
RELATIONSHIP BETWEEN RELATIVE TOXICITIES OF DIFFERENT STXS FOR MICE AND VIRULENCE OF STEC IN A MOUSE ORAL INFECTION MODEL
Mouse model for O157:H7 and non-O157 STEC We previously showed that streptomycin (str)-treated outbred CD-1 mice succumbed to infection when fed 1010 organisms of a mouse-passaged strain of E. coil O157:H7 strain 933cu (cu for cured of its large plasmid), even though neither the parent 933cu strain nor 933 was virulent at 1010 organisms (23). We later found that this mouse-virulent strain, designated 933cu-rev, had acquired the capacity to grow on the distal small bowel epithelium and in mouse small intestinal mucus (23). We speculated that these acquired traits permitted increased systemic toxin delivery from the intestine compared to the parent 933cu strain. We also discovered that death of the mice fed 933cu-rev was due to tubular necrosis mediated by Stx2, but not Stx1, produced by the strain (24). Subsequently, we tested a panel of Stxl-and/or Stx2-producing E. coil O157:H7 strains as well as non-O157 strains in the str-treated CD-1 mouse model. We now conclude that an STEC strain is likely to be pathogenic in this CD-1 model if it either: i.) grows in small-intestinal mucus, colonizes the large intestine of the mice, and makes Stx2 or Stx2c [high oral 50% lethal dose (LD so) or Stx2d (low oral LD so, see below) ; or ii.) synthesizes very high levels of Stx2, Stx2c, or Stx2d (as expressed from a clone) and colonizes only the large bowel [see Table 1 as well as refs. (10, 24) for details on relative virulence of STEC strains for CD-1 mice]. More recently, we discovered that certain E. coil O157:H7 strains that make Stx1 and Stx2 or Stx2 alone that are avirulent in str-treated CD-1 adult mice are pathogenic if fed to streptomycin-treated DBA/2J mice, Table 2 . As with 933cu-rev in CD-1 mice, it is Stx2 that kills DBA/2J mice fed a virulent E. coli O157 H7 strain that produces both Stx 1 and Stx2 (see Table 3 ). In fact, E. coli O 157:H7 strains that make Stx1 only are avirulent in DBA/2J mice. That Stx2 is about 400-fold more toxic for mice when injected parenterally than is Stx 1 [(21) and summarized in Table 1 ] probably explains the differences in virulence among these strains. Of note is the correlation between this observation that Stx2 and Stx2-related toxins contribute to virulence of STEC in a mouse model whereas Stxl does not, and the finding that Stx2-producing E. coli O157: H7 more frequently cause HUS than those that make Stx 1 only (19). The fact that certain O 157:H7 strains that produce Stx2 or Stx2 and Stx1 are virulent in DBA/2J mice but not in CD-1 mice could be explained by differences in the size of the animals. Indeed, we speculate that virulence in this model is not only due to type of toxin but also level of toxin produced relative to body weight of the mouse. Four observations support various aspects of this hypothesis: i.) male DBA/2J mice weigh about 17g while adult CD-1 mice weigh about 24 g; ii.) a str-resistant E. coli K-12 strain transformed with a multicopy plasmid encoding Stx2 or Stx2d is sufficient to cause kidney damage and kill orally-infected adult CD-1 mice (11, 24); iii.) EHEC O157: H 7 strain 86-24 (Stx2-producer) has a low LD so in adult DBA/2J animals but a high LDso in adult CD-1 mice (see Table 1 ); and, iv.) adult inbred mice of approximately the same size as DBA/2J mice (C57BL/6J, BALB/cJ, and C3H/HeJ) are also susceptible to lethal infection with strain 86-24 (unpublished observation). Whatever the actual basis of the sensitivity of adult DBA/2J mice to many Stx2-or Stxl-and Stx2-producing E. coli O157: H7 strains, we propose that this mouse model is appropriate for evaluating relative virulence of such isolates.
Enhanced virulence of Stx2d-producing non-O157 strains in the CD-1 mouse model
When we began to screen various strains of STEC for mouse virulence, we made the startling discovery that STEC O91:H21 strain B2F1 killed str-treated adult CD-1 mice when fed at doses as low as 10 organisms (10). We also identified another O91:H21 strain, designated H414-36/89 (10), that was similarly virulent for these large mice. We proposed that the extraordinary pathogenicity of these isolates might be due to the production Stx2d toxins [originally called Stx2vh, see ref. (10)] by these strains. In fact, we later showed that the toxicity of Stx2d can be increased (activated) by exposure to mouse or human colonic mucus and that this capacity for activation is unique to the Stx2d variant of Stx2 [see Table 1 and ref. (13)]. More recently, we identified other non-O157 STEC strains that are highly virulent for str-treated CD-1 mice [e.g. an O104:H21 isolate, 3024-94, that caused an outbreak of hemorrhagic colitis in the U.S. in 1994 (1)] and found that they also make Stx2d (unpublished finding). To date Stx2d is the only Stx that we have identified which can be activated by intestinal mucus. The only amino acid differences that can account for the fact that Stx2d is activatable but not Stx2 or Stx2c (13) are two amino acids in the C-terminus of the Aa fragment of those toxins (13). We are in the process of identifying which of these amino acids are critical for activation and defining the biochemical basis for activation. We also intend to explore how activation actually translates into increased toxicity.
CONCLUSION
The type of Stx produced by an infecting STEC strain directly relates to its virulence in a str-treated orally infected mouse model: Stx/Stxl is less toxic than Stx2 or Stx2c, and Stx2 and Stx2c are less toxic than Stx2d. Adult CD-1 mice are less sensitive than DBA/ 2J mice to these toxins as delivered following oral infection; hence, the DBA/2J model can be used to screen Stx2 + O157: H7 strains for relative virulence. Finally, S112 
